Literature DB >> 16421174

Prognostic significance of plasma osteopontin levels in patients with chronic stable angina.

Piercarlo Minoretti1, Colomba Falcone, Margherita Calcagnino, Enzo Emanuele, Maria P Buzzi, Enrico Coen, Diego Geroldi.   

Abstract

AIMS: Levels of the secreted glycophosphoprotein osteopontin (OPN) have been associated with the presence and extent of coronary artery disease (CAD). The present study assessed the relationship between plasma OPN concentrations and prognosis in patients with chronic stable angina (CSA). METHODS AND
RESULTS: OPN was measured in baseline plasma samples from 799 patients with stable angina pectoris and angiographically documented CAD. Participants were prospectively followed-up for a median of 2.7 years (maximum 4.1 years). The primary study endpoint was the composite of non-fatal myocardial infarction and death from cardiovascular causes. In the univariate Cox proportional hazard analysis, the log-transformed OPN level [hazard ratio (HR) 1.79, 95% CI 1.35-2.36, P < 0.001] was significantly related to adverse outcome. In addition, hypertension, levels of C-reactive protein, and statin use were associated with future adverse events. Levels of OPN (HR, 1.88; P < 0.001) and C-reactive protein (HR, 1.42; P = 0.003), as well as the presence of hypertension (HR, 2.39; P = 0.008) remained statistically significant, independent predictors of adverse cardiovascular outcome in a multivariable Cox proportional hazard analysis.
CONCLUSION: Baseline levels of OPN are an independent predictor of future adverse cardiac events in patients with CSA and may be useful for risk stratification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16421174     DOI: 10.1093/eurheartj/ehi730

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  20 in total

1.  Clinical outcomes of lung metastasectomy in patients with colorectal cancer.

Authors:  Omer Fatih Olmez; Erdem Cubukcu; Ahmet Sami Bayram; Unsal Akcali; Turkkan Evrensel; Cengiz Gebitekin
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

2.  Plasma osteopontin as a predictor of coronary artery disease: association with echocardiographic characteristics of atherosclerosis.

Authors:  Hala Abdel-Hameed Abdel-Azeez; Manar Al-Zaky
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  Dephosphorylation of circulating human osteopontin correlates with severe valvular calcification in patients with calcific aortic valve disease.

Authors:  Rachana Sainger; Juan B Grau; Paolo Poggio; Emanuela Branchetti; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Giovanni Ferrari
Journal:  Biomarkers       Date:  2011-12-23       Impact factor: 2.658

4.  The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.

Authors:  O F Olmez; E Cubukcu; T Evrensel; M Kurt; N Avci; S Tolunay; A Bekar; A Deligonul; M Hartavi; N Alkis; O Manavoglu
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

5.  Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

Authors:  Simone H Mangan; Ann Van Campenhout; Catherine Rush; Jonathan Golledge
Journal:  Cardiovasc Res       Date:  2007-08-02       Impact factor: 10.787

6.  Association of plasma osteopontin levels with coronary calcification evaluated by tomographic coronary calcium scoring.

Authors:  Muhammedullah Aryan; Alper Kepez; Enver Atalar; Tuncay Hazirolan; Ibrahim Haznedaroglu; Deniz Akata; Necla Ozer; Serdar Aksoyek; Kanan Ovunc; Ferhan Ozmen
Journal:  J Bone Miner Metab       Date:  2009-04-14       Impact factor: 2.626

Review 7.  Osteopontin and cardiovascular system.

Authors:  Hiroshi Okamoto
Journal:  Mol Cell Biochem       Date:  2006-11-30       Impact factor: 3.842

8.  Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus.

Authors:  Xiaoxiang Yan; Motoaki Sano; Lin Lu; Wei Wang; Qi Zhang; Ruiyan Zhang; Lingjie Wang; Qiujing Chen; Keiichi Fukuda; Weifeng Shen
Journal:  Cardiovasc Diabetol       Date:  2010-10-29       Impact factor: 9.951

9.  Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy.

Authors:  Hiromi Tachibana; Daisuke Ogawa; Yuichi Matsushita; Dennis Bruemmer; Jun Wada; Sanae Teshigawara; Jun Eguchi; Chikage Sato-Horiguchi; Haruhito Adam Uchida; Kenichi Shikata; Hirofumi Makino
Journal:  J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 10.121

10.  Impaired renal function impacts negatively on vascular stiffness in patients with coronary artery disease.

Authors:  Sabrina H Rossi; Emily P McQuarrie; William H Miller; Ruth M Mackenzie; Jane A Dymott; María U Moreno; Chiara Taurino; Ashley M Miller; Ulf Neisius; Geoffrey A Berg; Zivile Valuckiene; Jonathan A Hannay; Anna F Dominiczak; Christian Delles
Journal:  BMC Nephrol       Date:  2013-08-13       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.